stockportfolio.pro
Phibro Animal Health Corporation (PAHC)
Healthcare · Drug Manufacturers - Specialty & Generic · NasdaqGM
Phibro Animal Health Corporation revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $751.53M | $764.28M | $819.98M | $828.00M | $800.35M | $833.35M | $942.26M | $977.90M | $1.02B | $1.30B |
| Gross profit | $239.03M | $248.24M | $266.88M | $264.62M | $256.88M | $271.38M | $285.40M | $298.24M | $313.09M | $399.94M |
| Net income | $82.73M | $64.61M | $64.88M | $54.71M | $33.55M | $54.38M | $49.17M | $32.60M | $2.40M | $48.30M |
| Net margin | 11.0% | 8.5% | 7.9% | 6.6% | 4.2% | 6.5% | 5.2% | 3.3% | 0.2% | 3.7% |
Source: Phibro Animal Health Corporation SEC filings (10-K). 14 years of history available in the interactive view.
What growth is priced into PAHC stock?
At today's market cap of $1.28B, Phibro Animal Health Corporation is priced for free-cash-flow growth of about 13.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $41.83M from the FY ending 2025-06-30). For comparison, free cash flow actually grew 10.6%/yr over the last five fiscal years and revenue 10.1%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 14 years of Phibro Animal Health Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track PAHC in your portfolio →
Phibro Animal Health Corporation financial history by metric
About Phibro Animal Health Corporation
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey.
Phibro Animal Health Corporation — frequently asked questions
What is Phibro Animal Health Corporation's revenue?
Phibro Animal Health Corporation (PAHC) reported revenue of $1.30B for fiscal year 2025, up 27.4% from the prior year, according to its SEC filings.
Is Phibro Animal Health Corporation profitable?
Yes. PAHC earned net income of $48.30M in fiscal 2025, a net margin of 3.7%.
What is PAHC's P/E ratio?
Phibro Animal Health Corporation trades at a price-to-earnings ratio of about 13.6 based on the latest data in our nightly-refreshed cache.
How fast is Phibro Animal Health Corporation growing?
PAHC's revenue grew at roughly 10.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Phibro Animal Health Corporation have?
As of fiscal year 2025, PAHC carried roughly $631.68M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Phibro Animal Health Corporation's gross margin?
PAHC's gross margin was 30.9% in fiscal 2025 — gross profit of $399.94M on revenue of $1.30B.
What is Phibro Animal Health Corporation's market cap?
Phibro Animal Health Corporation (PAHC) has a market capitalization of about $1.28B, based on the latest data in our nightly-refreshed cache.
When does Phibro Animal Health Corporation's fiscal year end?
PAHC's fiscal year ends in June. Its most recent annual filing covers the fiscal year ending 2025-06-30.
What growth is priced into PAHC stock?
At today's market cap of $1.28B, Phibro Animal Health Corporation is priced for free-cash-flow growth of about 13.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $41.83M from the FY ending 2025-06-30). For comparison, free cash flow actually grew 10.6%/yr over the last five fiscal years and revenue 10.1%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Phibro Animal Health Corporation's official SEC filings (10-K and 10-Q), covering 14 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.